ArticleCancer cell2019
KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance.
Article in Cancer cell, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Targeting the Chromatin-Modifying Enzyme, KDM5C, Enhances AKT Inhibition Response in ER+ Breast Cancer.Molecular cancer therapeutics · 2026Article
- EpiCHAOS: a metric to quantify epigenomic heterogeneity in single-cell data.Genome biology · 2024Article
- DrugFormer: Graph-Enhanced Language Model to Predict Drug Sensitivity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Review
- DRMref: comprehensive reference map of drug resistance mechanisms in human cancer.Nucleic acids research · 2024Article
- A war on many fronts: cross disciplinary approaches for novel cancer treatment strategies.Frontiers in genetics · 2024Review
- MAF amplification licenses ERα through epigenetic remodelling to drive breast cancer metastasis.Nature cell biology · 2023Article
- JAK-STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States.Cancer research · 2023Article
- Identification and validation of endocrine resistance-related and immune-related long non-coding RNA (lncRNA) signatures for predicting endocrinotherapy response and prognosis in breast cancer.Annals of translational medicine · 2022Article
- Subclonal heterogeneity and evolution in breast cancer.NPJ breast cancer · 2021Review
- Cancer cell states and emergent properties of the dynamic tumor system.Genome research · 2021Article
- A combination approach of pseudotime analysis and mathematical modeling for understanding drug-resistant mechanisms.Scientific reports · 2021Article
- KDM5A suppresses PML-RARα target gene expression and APL differentiation through repressing H3K4me2.Blood advances · 2021Article
- Single-cell RNA sequencing in cancer: Applications, advances, and emerging challenges.Molecular therapy oncolytics · 2021Review
- Spontaneous cell fusions as a mechanism of parasexual recombination in tumour cell populations.Nature ecology & evolution · 2021Article
- Laboratory Models for Investigating Breast Cancer Therapy Resistance and Metastasis.Frontiers in oncology · 2021Review
- Methodological Advancements for Investigating Intra-tumoral Heterogeneity in Breast Cancer at the Bench and Bedside.Journal of mammary gland biology and neoplasia · 2020Article
- Evidence for context-dependent functions of KDM5B in prostate development and prostate cancer.Oncotarget · 2020Article
- Overcoming Endocrine Resistance in Breast Cancer.Cancer cell · 2020Review
- Review
Corrections and comments
- Erratum for
Authors and funding
28 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.